Poolbeg Pharma PLC Cash Flow Conversion Efficiency

Latest as of December 2025: -0.251x

Poolbeg Pharma PLC cash flow conversion efficiency. Based on the latest financial reports, Poolbeg Pharma PLC (POLB) has a cash flow conversion efficiency ratio of -0.251x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.16 Million ≈ $-263.05 USD) by net assets (GBX8.60 Million ≈ $1.05K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Poolbeg Pharma PLC (2021–2025)

Cash flow conversion efficiency of Poolbeg Pharma PLC from 2021 to 2025. This chart illustrates how Poolbeg Pharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Poolbeg Pharma PLC (POLB) share price today for real-time trading data and today's change.

Poolbeg Pharma PLC Cash Flow Conversion Ratio Explained

Poolbeg Pharma PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Poolbeg Pharma PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Poolbeg Pharma PLC ranked by their cash flow conversion efficiency. Also see market value of Poolbeg Pharma PLC for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
LeoNovus Inc V:LTV	-0.001x
IRWIN NATURALS INC. F:97X	N/A
Pioneering Technology Corp V:PTE	0.016x
EPE Special Opportunities Limited LSE:ESO	-0.012x
Starwood European Real Estate Finance Ltd LSE:SWEF	0.144x
Waseco Resources Inc. V:WRI	0.003x
Volvere PLC LSE:VLE	0.004x
Vitality Products Inc V:VPI	0.015x

Annual Cash Flow Conversion Efficiency for Poolbeg Pharma PLC (2021–2025)

The table below shows the annual cash flow conversion efficiency of Poolbeg Pharma PLC from 2021 to 2025. Review Poolbeg Pharma PLC free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	GBX8.60 Million ≈ $1.05K	GBX-4.51 Million ≈ $-548.49	-0.524x	-4.61%
2024-12-31	GBX9.27 Million ≈ $1.13K	GBX-4.65 Million ≈ $-565.28	-0.501x	-65.16%
2023-12-31	GBX14.44 Million ≈ $1.76K	GBX-4.38 Million ≈ $-533.04	-0.303x	-27.25%
2022-12-31	GBX18.32 Million ≈ $2.23K	GBX-4.37 Million ≈ $-531.46	-0.238x	-150.83%
2021-12-31	GBX22.58 Million ≈ $2.75K	GBX-2.15 Million ≈ $-261.11	-0.095x	--

About Poolbeg Pharma PLC

LSE:POLB UK Biotechnology

Market Cap

$603.77K

GBX4.96 Billion GBX

Market Cap Rank

#30979 Global

#894 in UK

Share Price

GBX6.50

Change (1 day)

+0.00%

52-Week Range

GBX3.55 - GBX9.05

All Time High

GBX14.90